{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:55:29Z","timestamp":1789167329615,"version":"build-2803163510"},"reference-count":50,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The development of effective viroimmunotherapies for cancer relies on the ability of replicating viruses to infect the entire tumor tissue and induce comprehensive inflammation within the tumor microenvironment (TME). In this study, we investigate the impact of mutations in the glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV) on tumor cell infectivity, replication, and the immune response. Specifically, we focus on two key positions in GP1 (181 and 185) that significantly enhance tumor cell infectivity and improve CD8+ T cell function in the GP-mutated LCMV strain LCMV P52. Our findings demonstrate that LCMV strain LCMV P52 replicates preferentially in vivo in tumors, exhibits improved tumor penetration, attracts functional CD8+ T cells more effectively to the tumor, and reprograms the tumor toward a more immunogenic microenvironment to allow for effective checkpoint inhibitor combination.<\/jats:p>","DOI":"10.3390\/v18090998","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:09:40Z","timestamp":1789117780000},"page":"998","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lymphocytic Choriomeningitis Virus Bearing GPC Mutations for Enhanced Tumor Tropism and Strong Anti-Tumor Activity"],"prefix":"10.3390","volume":"18","author":[{"given":"Sarah-Kim","family":"Friedrich-Becker","sequence":"first","affiliation":[{"name":"Abalos Therapeutics GmbH, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2900-6983","authenticated-orcid":false,"given":"Michael","family":"Bergerhausen","sequence":"additional","affiliation":[{"name":"Abalos Therapeutics GmbH, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"given":"Arshia","family":"Berry","sequence":"additional","affiliation":[{"name":"Abalos Therapeutics GmbH, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Hilal","family":"Bhat","sequence":"additional","affiliation":[{"name":"Institute of Immunology, University Hospital of Essen, 45147 Essen, Germany"},{"name":"National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, 01309 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Fanghui","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Immunology, University Hospital of Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3578-7179","authenticated-orcid":false,"given":"Rosa","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Institute of Immunology, University Hospital of Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5339-6942","authenticated-orcid":false,"given":"Lisa","family":"Holnsteiner","sequence":"additional","affiliation":[{"name":"Institute of Immunology, University Hospital of Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Dethardt","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Abalos Therapeutics GmbH, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]},{"given":"Haifeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine II, Medical Faculty, Heinrich Heine University, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Philipp A.","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine II, Medical Faculty, Heinrich Heine University, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Sebastian","family":"Lang","sequence":"additional","affiliation":[{"name":"Institute of Immunology, University Hospital of Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]},{"given":"J\u00f6rg","family":"Vollmer","sequence":"additional","affiliation":[{"name":"Abalos Therapeutics GmbH, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12943-025-02477-6","article-title":"Turning cold tumors into hot tumors to ignite immunotherapy","volume":"24","author":"Liu","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1126\/science.abk3436","article-title":"Oncolytic virotherapy as immunotherapy","volume":"374","author":"Melcher","year":"2021","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e1442169","DOI":"10.1080\/2162402X.2018.1442169","article-title":"Heating it up: Oncolytic viruses make tumors \u2018hot\u2019 and suitable for checkpoint blockade immunotherapies","volume":"7","author":"Gujar","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"117194","DOI":"10.1016\/j.bcp.2025.117194","article-title":"Transforming the \u201ccold\u201d tumors to \u201chot\u201d tumors: Strategies for immune activation","volume":"241","author":"Kong","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"ref_6","first-page":"164","article-title":"Therapeutic Implementation of Oncolytic Viruses for Cancer Immunotherapy: Review of Challenges and Current Clinical Trials","volume":"4","author":"Wang","year":"2022","journal-title":"J. Biomed. Sci. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s44337-025-00328-3","article-title":"Exploring the potential of oncolytic viral vectors in targeted cancer therapy: Advances, challenges and future directions","volume":"2","author":"Ghosh","year":"2025","journal-title":"Discov. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2019.03.001","article-title":"Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors","volume":"13","author":"Pearl","year":"2019","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0042-6822(89)90216-X","article-title":"The completed sequence of lymphocytic choriomeningitis virus reveals a unique RNA structure and a gene for a zinc finger protein","volume":"173","author":"Salvato","year":"1989","journal-title":"Virology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1128\/jvi.53.3.966-968.1985","article-title":"The S RNA segment of lymphocytic choriomeningitis virus codes for the nucleoprotein and glycoproteins 1 and 2","volume":"53","author":"Riviere","year":"1985","journal-title":"J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1128\/JVI.76.12.6393-6397.2002","article-title":"Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles","volume":"76","author":"Lee","year":"2002","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/viro.1994.1001","article-title":"Mechanism of lymphocytic choriomeningitis virus entry into cells","volume":"198","author":"Borrow","year":"1994","journal-title":"Virology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.chembiol.2023.03.005","article-title":"Structural basis for antibody-mediated neutralization of lymphocytic choriomeningitis virus","volume":"30","author":"Zhang","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1128\/JVI.75.2.1061-1064.2001","article-title":"Recombinant expression of lymphocytic choriomeningitis virus strain WE glycoproteins: A single amino acid makes the difference","volume":"75","author":"Beyer","year":"2001","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1479-0556-9-8","article-title":"Altering \u03b1-dystroglycan receptor affinity of LCMV pseudotyped lentivirus yields unique cell and tissue tropism","volume":"9","author":"Dylla","year":"2011","journal-title":"Genet. Vaccines Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"102411","DOI":"10.1016\/j.xcrm.2025.102411","article-title":"Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties","volume":"6","author":"Lang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14447","DOI":"10.1038\/ncomms14447","article-title":"Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression","volume":"8","author":"Kalkavan","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Honke, N., Shaabani, N., Zhang, D.-E., Iliakis, G., Xu, H.C., H\u00e4ussinger, D., Recher, M., L\u00f6hning, M., Lang, P.A., and Lang, K.S. (2013). Usp18 Driven Enforced Viral Replication in Dendritic Cells Contributes to Break of Immunological Tolerance in Autoimmune Diabetes. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003650"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.4049\/jimmunol.0900592","article-title":"Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory","volume":"183","author":"Agarwal","year":"2009","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.immuni.2011.07.010","article-title":"CD8+ T cells: Foot soldiers of the immune system","volume":"35","author":"Zhang","year":"2011","journal-title":"Immunity"},{"key":"ref_24","unstructured":"Bergerhausen, M., Holnsteiner, L., Friedrich-Becker, S.-K., Hu, Z., Schmitz, R., M\u00fcller, D., Kostka, M., Brandenberg, T., Xu, H.C., and Hardt, C. (2026). Mutations at positions 181 and 185 within the LCMV GP protein increase tumor cell infectivity, limit induction of type I interferon, and accelerate T cell activation. Viruses, in press."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nsmb.3210","article-title":"Crystal structure of the prefusion surface glycoprotein of the prototypic arenavirus LCMV","volume":"23","author":"Hastie","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1126\/science.aam7260","article-title":"Structural basis for antibody-mediated neutralization of Lassa virus","volume":"356","author":"Hastie","year":"2017","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.4049\/jimmunol.2300637","article-title":"High-Affinity-Mediated Viral Entry Triggers Innate Affinity Escape Resulting in Type I IFN Resistance and Impaired T Cell Immunity","volume":"212","author":"Xu","year":"2024","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1128\/JVI.01459-06","article-title":"Quantitating the Magnitude of the Lymphocytic Choriomeningitis Virus-Specific CD8 T-Cell Response: It Is Even Bigger than We Thought","volume":"81","author":"Masopust","year":"2007","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Buchmeier, M.J., Welsh, R.M., Dutko, F.J., and Oldstone, M.B. (1980). The Virology and Immunobiology of Lymphocytic Choriomeningitis Virus Infection, Elesevier. Advances in Immunology.","DOI":"10.1016\/S0065-2776(08)60197-2"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.celrep.2019.04.004","article-title":"Identification of a Locus in Mice that Regulates the Collateral Damage and Lethality of Virus Infection","volume":"27","author":"Misumi","year":"2019","journal-title":"Cell Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1128\/jvi.76.5.2375-2383.2002","article-title":"Role of an intact splenic microarchitecture in early lymphocytic choriomeningitis virus production","volume":"76","author":"Hunziker","year":"2002","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"16071","DOI":"10.1073\/pnas.2232366100","article-title":"Targeting Schwann cells by nonlytic arenaviral infection selectively inhibits myelination","volume":"100","author":"Rambukkana","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Schnell, F.J., Sundholm, S., Crumley, S., Iversen, P.L., and Mourich, D.V. (2012). Lymphocytic choriomeningitis virus infection in FVB mouse produces hemorrhagic disease. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1003073"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/jps.22811","article-title":"Interspecies Scaling in Pharmacokinetics: A Novel Whole-Body Physiologically Based Modeling Framework to Discover Drug Biodistribution Mechanisms in vivo","volume":"101","author":"Hall","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7578","DOI":"10.1128\/JVI.03117-13","article-title":"IRF7-dependent type I interferon production induces lethal immune-mediated disease in STAT1 knockout mice infected with lymphocytic choriomeningitis virus","volume":"88","author":"Li","year":"2014","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"108348","DOI":"10.1016\/j.isci.2023.108348","article-title":"Mice with FVB-derived sequence on chromosome 17 succumb to disseminated virus infection due to aberrant NK cell and T cell responses","volume":"26","author":"Tibbs","year":"2023","journal-title":"iScience"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1099\/vir.0.82428-0","article-title":"Contributions of the lymphocytic choriomeningitis virus glycoprotein and polymerase to strain-specific differences in murine liver pathogenicity","volume":"88","author":"Bergthaler","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"201082","DOI":"10.1016\/j.omton.2025.201082","article-title":"Dual-cytokine-armed oncolytic HSV for enhanced tumor immunotherapy","volume":"33","author":"Dhital","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Fayyad-Kazan, M., Al-Tameemi, S., and Ouhtit, A. (2026). Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation. Cells, 15.","DOI":"10.3390\/cells15050393"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1128\/JVI.72.3.2253-2258.1998","article-title":"Enhanced virus clearance by early inducible lymphocytic choriomeningitis virus-neutralizing antibodies in immunoglobulin-transgenic mice","volume":"72","author":"Seiler","year":"1998","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"136.12","DOI":"10.4049\/jimmunol.184.Supp.136.12","article-title":"Modulation of the RIG-I\/MDA5-MAVS-dependent signaling pathway by distinct LCMV components shapes type I interferon responses (136.12)","volume":"184","author":"Zhou","year":"2010","journal-title":"J. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.chom.2012.04.016","article-title":"Toll-like receptor 7 is required for effective adaptive immune responses that prevent persistent virus infection","volume":"11","author":"Walsh","year":"2012","journal-title":"Cell Host Microbe"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"13426","DOI":"10.1073\/pnas.0704423104","article-title":"A lymphocytic choriomeningitis virus glycoprotein variant that is retained in the endoplasmic reticulum efficiently cross-primes CD8+ T cell responses","volume":"104","author":"Freigang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e2119676119","DOI":"10.1073\/pnas.2119676119","article-title":"CD164 is a host factor for lymphocytic choriomeningitis virus entry","volume":"119","author":"Bakkers","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1158\/2767-9764.CRC-24-0434","article-title":"Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy","volume":"5","author":"Diers","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Chen, H., Xu, Z., and Varner, J. (2025). Targeting myeloid cells to improve cancer immune therapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1623436"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e012743","DOI":"10.1136\/jitc-2025-012743","article-title":"Positive and negative roles of myeloid cells in cancer immunotherapy","volume":"13","author":"Zak","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13046-026-03656-z","article-title":"Rewiring tumor cytokine networks to enhance immune checkpoint blockade: Mechanisms, engineering, and clinical translation","volume":"45","author":"Wang","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Meza Pacheco, M.F., and Tai, L.-H. (2025). Reprogramming the tumor microenvironment to boost adoptive T cell therapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1677548"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Czajka-Francuz, P., Prendes, M.J., Mankan, A., Quintana, \u00c1., Pabla, S., Ramkissoon, S., Jensen, T.J., Peir\u00f3, S., Severson, E.A., and Achyut, B.R. (2023). Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1200646"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/9\/998\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:12:28Z","timestamp":1789117948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/9\/998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["v18090998"],"URL":"https:\/\/doi.org\/10.3390\/v18090998","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}